Emcitate
·
- Prescription status not stated
- Hormones, such as thyroid and steroids
- Active substance
- Tiratricol
- Made by
- Rare Thyroid Therapeutics International AB
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Emcitate is indicated for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley Syndrome), from birth.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Rare Thyroid Therapeutics International AB |
|---|---|
| Active substance | Tiratricol |
| Used in | Hormones, such as thyroid and steroids |
| Classification | H03AA04 · Hormones, such as thyroid and steroids |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Authorised on | 2025-02-12 |
| Last updated by the regulator | 2025-03-11 |
| EMA product number | EMEA/H/C/005220 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).